The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX).
Urban Emmenegger
No relevant relationships to disclose
Christopher M. Booth
No relevant relationships to disclose
Scott R. Berry
No relevant relationships to disclose
Srikala S. Sridhar
No relevant relationships to disclose
Eric Winquist
No relevant relationships to disclose
Nesan Bandali
No relevant relationships to disclose
Annabelle Chow
No relevant relationships to disclose
Christina R. Lee
No relevant relationships to disclose
Ping Xu
No relevant relationships to disclose
Shan Man
No relevant relationships to disclose
Robert S. Kerbel
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Yoo-Joung Ko
No relevant relationships to disclose